Mikhail Blagosklonny: Researcher extraordinaire.

Dr. Mikhail Blagosklonny is truly a gifted and dedicated human being. With hard work, Dr. Mikhail Blagosklonny earned his M.D and PhD in experimental medicine and cardiology from First Pavlov State Medical University of St. Petersburg. Dr. Mikhail Blagosklonny has dedicated his life to the study of The mechanistic target of rapamycin (mTOR), also known as FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1) and its possible role in aiding of cancer and the eradication of cancer.

Dr. Mikhail Blagosklonny is also the editor-in-chief of Oncotarget, a journal based around all things oncology. The Journal’s first volume was published in May of 2010, and has many interesting articles, some of which were penned by Dr. Mikhail Blagosklonny himself. Further to his duties as editor-in-chief at Oncotarget, he is also an editor-in-chief for the journals named Aging and Cell Cycle. What’s more, Dr. Mikhail Blagosklonny has penned hundreds of articles that have contributed precious and thought provoking knowledge to the medical community and scholars alike. He is dedicated to the integrity of any article he puts his name to and strenuously vets anything that crosses his desk as editor.

Furthermore, Dr. Mikhail Blagosklonny has dedicated his life to finding a cure for cancer and continues his research on cancer and anti aging to this very day. Dr. Mikhail Blagosklonny truly believes that we can have a world free from cancer. This is why he is a proponent of the cancer drug called Rapamycin. The drug is also known as Sirolimus and is a macrolide compound which has multiple uses such as an aid in the prevention of organ transplant rejection.

Moreover, Dr. Mikhail Blagosklonny second passion, anti-aging could also one day be a reality. With his continued research in the field, Dr. Mikhail Blagosklonny has made several exciting discoveries and may be close to unlocking the fountain of youth. In his journal, Oncotarget, he published an update to the study called, Rejuvenating immunity: “anti-aging drug today” eight years later which highlights the advances in Everolimus, a rapamycin analog which was shown to increase immunity in the elderly.

Dr. Mikhail Blagosklonny is an innovator and selfless human being whose work is of the utmost importance to humanity. With his tireless work, we may hopefully see a cure for cancer in our lifetime.

Leave a Reply

Your email address will not be published. Required fields are marked *